Nautilus Biotechnology (NAUT) Q1 2026 earnings summary

Executive summary

• Advanced commercialization roadmap with key 2026 milestones, including expanding early access programs and preparing for commercial launch in late 2026 with installations in early 2027; focus remains on scaling Early Access and progressing toward full commercial availability of the Voyager platform.

• Initiated Iterative Mapping Early Access Program, expanding access to Tau proteoform assay with Baylor College of Medicine as the first customer in an NIH-funded cancer study; strong interest from academic, nonprofit, and biopharma sectors.

• Built out commercial team, hiring a VP of Global Sales and two additional sales members to drive customer engagement and Early Access expansion.

• Early access engagements focus on enabling biological discovery and supporting publications, not near-term revenue.

• Company continues to invest heavily in R&D and commercialization infrastructure, with significant losses expected for the foreseeable future.

Financial highlights

• Total operating expenses for Q1 2026 were $16.1 million, down 14% year-over-year, primarily due to lower salaries, benefits, stock-based compensation, and facilities costs.

• Net loss for Q1 2026 was $14.7 million, a 12% improvement from $16.6 million in Q1 2025.

• Research and development expenses were $9.7 million, a 16% decrease from the prior year.

• General and administrative expenses were $6.4 million, down 12% year-over-year.

• Cash, cash equivalents, and investments totaled $143.4 million as of March 31, 2026; Q1 cash burn was $12.8 million.

Outlook and guidance

• Commercial launch planned for late 2026, with pre-orders and installations beginning early 2027 and broad scale capabilities available in the first half of 2027.

• Oncology-focused proteoform assay expected to enter early access in the second half of 2026.

• Financial plan supports a cash runway through 2027; current cash and investments expected to fund operations for at least the next 12 months.

• No material revenue anticipated from early access activities; commercial revenue expected post-2027.

• Expenses and capital requirements projected to increase as the company advances product development and commercialization.